Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REZILIENT4 adjuvant zipalertinib versus placebo in resected EGFR-uncommon NSCLC
jRCT2051250089Phase 3Recruiting
- Sponsor
- Taiho Pharmaceutical Co., Ltd.
- Start
- Jan 2026
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in non-small cell lung cancer (NSCLC) comparing Zipalertinib with Placebo (2 arms). Primary endpoint: Disease-free survival. Started Jan 2026; status: recruiting.
02
Drugs
zipalertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCT2051250089.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051250089.